|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
4621 Technology Drive, Golden, CO 80403, US
|
|
Vitro Biopharma is an innovative biotechnology company focused on developing Wharton's jelly-derived cell therapies and targeting autoimmune diseases and inflammatory disorders. Our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market. AlloRx Stem Cell therapy is intended to be an “off-the-shelf” commercialized product that is stored frozen and available for on demand use. Our pipeline includes four core development programs. We intend to initiate our clinical trials for Long COVID and PTHS in late 2022 or 2023. In addition, we are also currently focused on our pre clinical development programs for MS and Lupus/SLE.
Our research products include:
a) Cell Culture Media
-We offer various formulations of MSCs and primary cell cultures with numerous competitive advantages.
b) Various Cell Lines
-Our cell lines include Umbilical Cord Blood derived MSCs, Adipose derived MSCs, Fluorescent Labeled MSCs, Cancer Associated Fibroblasts (CAFs), and Differentiated MSCs
c) Brain-Grow Technologies
-Neurological and Inflammatory Biomarker Profiling and Nutraceutical Recovery Packages
|
Vitro Biopharma, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Vitro Biopharma, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Vitro Biopharma, Inc. customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.